VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Lymphoma, Myeloma & Leukemia

• Publication date

  2016-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clml.2016.02.042PMID 27025160
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.

  2013cited by this paper
• Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.

  2013cited by this paper
• Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

  2013cited by this paper
• PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

  2013cited by this paper
• Pomalidomide: First Global Approval

  2013cited by this paper
• Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

  2013cited by this paper
• Carfilzomib: A Second-Generation Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma

  2013cited by this paper
• Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

  2012cited by this paper
• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  2012cited by this paper
• An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

  2012cited by this paper
• Clinically relevant end points and new drug approvals for myeloma

  2008cited by this paper
• The potential of histone deacetylase inhibitors for the treatment of multiple myeloma

  2008cited by this paper
• Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

  2007cited by this paper
• Histone deacetylase inhibitors: molecular mechanisms of action

  2007cited by this paper
• Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

  2005cited by this paper
• Histone Acetylation-independent Effect of Histone Deacetylase Inhibitors on Akt through the Reshuffling of Protein Phosphatase 1 Complexes*

  2005cited by this paper
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.

  2005cited by this paper
• Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.

  2004cited by this paper
• Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

  2003cited by this paper
• Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation.

  2002cited by this paper
• Regulation and Destabilization of HIF-1 by ARD1-Mediated Acetylation

  2002cited by this paper

• Exploring viral mimicry combined with epigenetics and tumor immunity: new perspectives in cancer therapy

  2025cites this paper
• Deciphering the dynamics of histone acetylation and chromatin remodeling in multiple myeloma: a tale beyond the tails.

  2025cites this paper
• Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives

  2024cites this paper
• Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin’s Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen

  2023cites this paper
• Histone deacetylase‐based dual targeted inhibition in multiple myeloma

  2023cites this paper
• Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma

  2023cites this paper
• Multiple myeloma etiology and treatment

  2022cites this paper
• Randomized Controlled Trials versus Single Cohort Studies in Relapse Refractory Multiple Myeloma

  2021cites this paper
• Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma

  2021cites this paper
• Network-Based Systems Analysis Explains Sequence-Dependent Synergism of Bortezomib and Vorinostat in Multiple Myeloma

  2021cites this paper
• Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.

  2020cites this paper
• Hunting down the dominating subclone of cancer stem cells as a potential new therapeutic target in multiple myeloma: An artificial intelligence perspective

  2020cites this paper
• Efficacy of Panobinostat for the Treatment of Multiple Myeloma

  2020cites this paper
• A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma

  2019influential citation
• Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.

  2019cites this paper
• Bortezomib and Vorinostat Therapy as Maintenance Therapy after Autologous Transplant for Multiple Myeloma

  2019cites this paper
• The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer

  2018cites this paper
• The biological significance of histone modifiers in multiple myeloma: clinical applications

  2018cites this paper
• The safety of bortezomib for the treatment of multiple myeloma

  2018cites this paper
• Seeking Convergence and Cure with New Myeloma Therapies.

  2018cites this paper
• Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)

  2018cites this paper
• Chromatin dynamics at the core of kidney fibrosis.

  2018cites this paper
• Targeted activity of histone deacetylase inhibition in synovial sarcoma

  2017cites this paper
• Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics

  2017cites this paper
• The proteasome and proteasome inhibitors in multiple myeloma

  2017cites this paper
• A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.

  2017cites this paper
• Clinical Applications of Histone Deacetylase Inhibitors

  2017cites this paper
• HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma

  2017cites this paper
• A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide‐containing regimens

  2017cites this paper
• Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma.

  2016cites this paper
• Progress and Paradigms in Multiple Myeloma

  2016cites this paper
• Multiple Myeloma Epigenetics in the Biology and Treatment of Multiple Myeloma

  2016cites this paper
• Next Generation Antimyeloma Agents: A Review

  2016cites this paper